

# Farzaneh Dastan

Pharm.D. | Ph.D. | Clinical Pharmacy Specialist

Associate Professor, Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Email: [f\\_dastan@sbmu.ac.ir](mailto:f_dastan@sbmu.ac.ir)

[Fzh.dastan@gmail.com](mailto:Fzh.dastan@gmail.com)

[Google Scholar](#)

[LinkedIn](#)

Scopus Author ID: 55936204600

ORCID ID: 0000-0001-7253-4333

## Summary

Current academic faculty and an associate professor at Department of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran, and the Head of Pharmaceutical Care Ward at Dr. Masih Daneshvari Hospital, Tehran, Iran. A Ph.D. and residency program graduate in Clinical Pharmacy with over ten years of multidisciplinary research experience. Ph.D. work was focused on RCTs design and implementation through cardiopulmonary research, pharmacotherapy consultation, evaluating drug safety and efficacy, and bio/pharmaceutical analysis. Prior to this, worked as a pharmacist; she also actively partook in roles as a clinician, scientific advisor, and researcher in clinical and industrial settings. Her work and research experience have enriched her vision in both research and practice to promote public health.

## Research Interests

Pharmacokinetics, Clinical Trials (RCTs), Cardiovascular diseases, Cardiopulmonary Diseases, Infectious Disease, Critical Care, Pharmacotherapy, Clinical Pharmacology, Pharmacy Education

## Education

2010-2014; **Ph.D. in Clinical Pharmacy**, Tehran University of Medical Sciences, Tehran, Iran

Thesis: Evaluating the effects of L-carnitine on the prevention of perioperative atrial fibrillation following coronary artery bypass graft surgery

Advisor: Prof. M. Mojtahedzadeh

Supervisor: Prof. AH. Talasaz

2004-2010; **Doctor of Pharmacy (Pharm.D.)** Shahid Beheshti University of Medical Sciences, Tehran, Iran

Thesis: Determination of Isoniazid, rifampicin and pyrazinamide plasma concentration in pulmonary tuberculosis, and its relation to hepatotoxicity

Advisor: Prof. P. Tabarsi

Supervisor: Prof. F. Fahimi

## Skills

- Randomised Clinical Trials (RCTs) design, development, and implementation (mostly designed to result in optimal pharmaceutical care)
- Data analysis: MS Excel, GraphPad, SPSS
- Clinical pharmacokinetics (Calculation, TDMs)
- Pharmaceutical and bioanalysis: U/HPLC with UV, FL, MS/MS detection
- Proficiency in spoken and written English and Persian
- Teaching and/or scholarship within the discipline including designing, conducting and moderating assessment; implementing improvements informed by course evaluation activities and student feedback (Pharmacotherapy, Biochemistry, Pharmacy internship and externship, Pharmacokinetics, ...)
- Pharmacotherapy consultation
- Great experience on COVID-19 pharmacotherapy management
- Anticoagulation management services (inpatient and outpatient)
- Drug safety (drug-related morbidity, adverse drug reaction, dose individualization, interaction, special patient population monitoring, medication errors).
- Management and strategy (implementing management strategy in hospital pharmacy, reengineering of services to meet new demands, addressing leadership questions)
- Drug information (on a specific disease, development in information delivery)
- Clinical pharmacy (intervention, patient specific pharmacotherapy, outcome assessment)
- Hospital pharmacy practice (formulary management, DTC IV admixture)
- Pharmacoeconomics (DUR, Quality of life, Cost-effectiveness)
- Drug protocols and treatment guidelines: establishment, implementation and evaluation

## Work Experience

- 2015-Present; **Assistant/Associate Professor and Senior Lecturer of Clinical Pharmacy**, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
Tel: +98 (21) 882-00118  
Email: pr\_pharmacy@sbmu.ac.ir
- 2015-Present; **Head of Pharmaceutical Care Ward**, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
Tel: +98 (21) 2610-9503  
Email: info@nritld.ac.ir
- 2018-Present; **Head of Pharmacotherapy Clinic**, Masih Daneshvari Lung Transplantation Clinic, Tehran, Iran  
Tel: +98 (21) 2610-9503  
Email: info@nritld.ac.ir
- 2019-Present; **Advisor in research and development affairs**, vice-chancellor of Food and Drug Affairs, Ministry of Health, Tehran, Iran  
Tel: +98 (21) 84248  
Email: fdo@sbmu.ac.ir
- 2016-Present; **Research Scientist**, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases, Tehran, Iran  
Tel: +98 (21) 2610-9503

Email: info@nritld.ac.ir

- 2015-Present; **Advisor in Pharmacological Research**, Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran  
Tel: +98 (21) 2610-9503  
Email: info@nritld.ac.ir
- 2015-2018; **Product Manager**, Emad Darman Pars Co., Tehran, Iran  
Tel: +98 (21) 2676-1419  
Email: info@emaddarmanpars.com
- 2014-2015; **Medical Advisor**, Orchid Zist Pharmed Company, Tehran, Iran  
Tel: +98 (21) 8807-6438  
Email: info@orchidpharmed.com

### Editor and Reviewer

- Frontiers in Pharmacology (Impact Factor: 5.8), BMC (BioMed Central, Impact Factor: 8.77), Scientific Reports (Impact Factor: 5.13), Transfusion and Apheresis Science, Iranian Journal of Pharmaceutical Research (5-Year Journal Impact Factor: 1.998, Q1 journal) and Tanaffos (Pubmed)

### Honours and Awards

- Selected article for publication in Frontiers e-book, entitled AI-enabled Data Science for COVID-19, comprising highly-regarded articles featured in AI in COVID-19; 2022
- Best Poster at the second Asian-European Pharmacoepidemiology; 2019
- Best Poster at 22nd IPSS seminar; 2019
- Best Poster at the first Asian-European Pharmacoepidemiology; 2018
- Ranked 1st in management of resources and expenditures in the field of drug management (National Certification in the first national festival of hospital experiences in resource management); 2018
- Best oral presentation in 28th Cancer research center; 2017
- Best poster of the 2nd Iranian Clinical Pharmacy Congress; 2011
- Ranked 1st in Clinical Pharmacy PhD program Entrance Exam; 2010
- Selected as exceptional talent by National Elites Foundation; 2010

### Memberships

- Member of European Society of Cardiology, Since 2018
- Member of World Health Organization (WHO) research team in "Solidarity Trial", 2020
- Member of Medical Council of Iran, Ministry of Health, Since 2010
- Member of Iranian Society of Clinical Pharmacists, Since 2014
- Member of Pharmaceutical Sciences Research Center, Since 2010
- Member of Chronic Respiratory Diseases Research Center, 2015
- Member of National Scientific Committee of Coronavirus, Since 2020
- Chief of Drug and Therapeutics Committee, Masih Daneshvari Hospital, Since 2016
- Member of Educational Development Office Committee, SBMU, Tehran, Iran, 2018

## Publications

1. **Dastan F**, Jamaati HR, Barati S, et al. The Effects of Combination-therapy of Tocilizumab and Baricitinib on the Management of Severe COVID-19 Cases: A Randomized Open-label Clinical Trial. *Frontiers in Pharmacology-Pharmacology of Infectious Diseases*, 2023.
2. **Dastan F**, Barati S, Fakharian A, et al. Evaluating the Effects of Nebulized Tocilizumab versus Intravenous Tocilizumab in the Management of Severe Coronavirus Disease 2019 Cases: A Randomized Clinical Trial. *Biomedical and Biotechnology Research Journal*, 2023.
3. Rakhshan A, Farahbakhsh N, Khanbabaee G, et al. Evaluating the efficacy of inhaled amikacin as an adjunct to intravenous combination therapy (ceftazidime and amikacin) in pediatric cystic fibrosis pulmonary exacerbation. *Frontiers in Pharmacology*, 2023.
4. Jamaati H, Karimi S, **Dastan F**, et al. Effectiveness of different vaccine platforms in reducing mortality and length of ICU stay in severe and critical cases of COVID-19 in the Omicron variant era: A national cohort study in Iran. *Journal of Medical Virology* 2023.
5. Fatemi B, Rezaei S, **Dastan F**, et al. Efficacy of intravenous immunoglobulins (IVIG) in COVID-19 patients: a systematic review and meta-analysis. *Research in Pharmaceutical Sciences*, 2023.
6. Etemadi Toudeshki N, Ameri Ahmad Z, Dastan F, et al. The efficacy and safety of sitagliptin administration in patients with Covid-19: A randomized clinical trial. *BBRJ*, 2023.
7. Barati S, Faizabadi F, Khalaj H, et al. Evaluation of noscapine-licorice combination effects on cough relieving in COVID-19 outpatients: A randomized controlled trial. *Frontiers in Pharmacology*, 2023. **Dastan F (Corresponding Author)**
8. Eslaminejad A, Sharifi H, **Dastan F**, et al. Prevalence and Associated Factors of Osteoporosis in Chronic Obstructive Pulmonary Disease Patients. *Journal of Iranian Medical Council*, 2023.
9. Tolouian R, Tolouian A, **Dastan F**, et al. Antioxidants and cisplatin nephrotoxicity; an updated review on current knowledge. *Journal of Nephro pharmacology*, 2023.
10. Sadidi M, Zare A, **Dastan F**, et al. The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus. *Journal of Research in Medical Sciences*, 2022.
11. Jamaati H, Eskandari R, Sharif-Kashani B, et al. Hemoptysis Resolution with Rituximab in Behçet's Disease: A Case Report. *TANAFOS*, 2022. **Dastan F (Corresponding Author)**
12. Hajimoradi M, Sharif Kashani B, **Dastan F**, et al. Remdesivir associated sinus bradycardia in patients with COVID-19: A prospective longitudinal study. *Frontiers in pharmacology*, 2022.
13. **Dastan F**, Gholizadeh Niari B, Adimi Naghan P, et al. Evaluating the Effects of Agomelatine on Polysomnography Parameters in Patients with Obstructive Sleep Apnea. *Journal of Pharmacy & Pharmaceutical Sciences*, 2022.
14. Hooman N, Otukesh H, Hosseini R, et al. Elevated urinary CD80 excretion in children with steroid-responsive nephrotic syndrome. *Biomedical and Biotechnology Research Journal*, 2022.
15. Ahmadi ZH, Hamidia H, Eskandari R. The potential role of clinical pharmacist in the practice of heart transplantation. *International Pharmacy Acta*, 2022. **Dastan F (Corresponding Author)**
16. **Dastan F**, Heshmatnia J, Zarghi A, et al. Evaluating the Effects of Umifenovir Compared to Lopinavir/Ritonavir in the Management of Patients with COVID-19: A Randomized Controlled Trial. *Microbes, Infection and Chemotherapy*, 2022.
17. Feizabadi F, Abedini A, Salamzadeh J, et al. Study of the Effects of Melatonin on Sleep Disorders in Pulmonary Sarcoidosis Patients. *IJPR*, 2022. **Dastan F (Corresponding Author)**

18. Hashemian SMR, Jamaati H, Khalili-Pishkhani F, et al. Molnupiravir in Combination with Remdesivir for Severe COVID-19 Patients Admitted to Hospital: a Case Series. *Microbes, Infection and Chemotherapy*, 2022. **Dastan F (Corresponding Author)**
19. **Dastan F**, Afzal G, Ghadimi S, et al. Successful IgM-enriched immunoglobulin treatment in severe COVID-19 pneumonia: a case report. *Microbes, Infection and Chemotherapy*, 2022.
20. Mirenayat M, Abedini A, Kiani A, et al. National Research Institute of Tuberculosis and Lung Disease (NRTL) protocol for the treatment of patients with COVID-19. *IJPR*, 2022.
21. Kazemina N, Mehdizadeh M, Salamzadeh J, et al. The Evaluation of Melatonin Effects on Mobilization and Engraftment in Autologous Hematopoietic Stem Cell Transplant Recipients; A Randomized, Double-blind and Placebo-controlled Trial. *IJPR*, 2022.
22. Tabarsi P, Afzal G, Eskandari R, **Dastan F (Corresponding Author)**. Late Post-Coronavirus Disease 2019 Inflammatory Syndrome: A Case Experience with Tocilizumab. *Tanaffos*, 2021
23. Rezaei M, Barati S, Babamahmoodi A, et al. The Possible Role of Bruton Tyrosine Kinase (BTK) Inhibitors in the Treatment of COVID-19: A Review. *Current Therapeutic Research*, 2021. **Dastan F (Corresponding Author)**
24. Feizabadi F, Hashemian SMR, Mirshafiei Z, et al. The Potential Role of Aerosolized Colistin in the Ventilator-Associated Pneumonia Management Caused by Multidrug-Resistant Gram-Negative Bacteria: A Randomized Clinical Trial. *Journal of Pharmaceutical Care*, 2021. **Dastan F (Corresponding Author)**
25. Lotfi A, Mardani M, Abbasi G, et al. A Pregnant Woman with a Diagnosis of COVID-19 without Clinical Manifestations: A Case Report. *International Pharmacy Acta*, 2021. **Dastan F (Corresponding Author)**
26. Hakimizad R, Soltani R, Khorvash F, et al. The Effect of acetyl-L-carnitine, Alpha-lipoic Acid, and Coenzyme Q10 Combination in Preventing Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized, Double-blind, Placebo-controlled Clinical Trial. *IJPR*, 2021.
27. Yasari F, Naghashzadeh F, Barati S, et al. The Effects of Oral Pentoxifylline on the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease and Normal Renal Function: A Randomized Clinical Trial. *International Pharmacy Acta*, 2021. **Dastan F (Corresponding Author)**
28. Tabarsi P, Vahidi H, Saffaei A, et al. Favipiravir Effects on the Control of Clinical Symptoms of Hospitalized COVID-19 Cases: An Experience with Iranian Formulated Dosage Form. *IJPR*, 2021. **Dastan F (Corresponding Author)**
29. Barati S, Amini H, Ahamadi ZH, et al. Evaluating the Efficacy and Safety of Rivaroxaban Compared to Warfarin in Chronic Thromboembolic Pulmonary Hypertension Patients Undergoing Pulmonary Endarterectomy. *Revista Portuguesa de Cardiologia (Accepted)*, 2021. **Dastan F (Corresponding Author)**
30. Saffaei A, Tabarsi P, Abedini A, et al. Tocilizumab as a promising agent against COVID-19: Issues and challenges. *JRMS*, 2021. **Dastan F (Corresponding Author)**
31. Barati S, Hashemian SMR, Tabarsi P, et al. Combined Therapy of Ciclosporin Plus Favipiravir in the Management of Patients with Severe COVID-19, not Responding to Dexamethasone: A non-Controlled Prospective Trial. *International Immunopharmacology*, 2021. **Dastan F (Corresponding Author)**
32. Amirsavadvkouhi A, Jahangirifard A, Shahrami R, et al. The Role of Hemoperfusion in COVID-19 Infection: A Case Series. *Archives of Anesthesiology and Critical Care*, 2021. **Dastan F (Corresponding Author)**
33. Tabarsi P, Hashemian SMR, Bauhofer A, et al. IgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patients. *International Immunopharmacology*, 2021. **Dastan F (Corresponding Author)**

34. Fakharian A, Barati S, Mirenayat M, et al. Evaluation of Adalimumab Effects in Managing Severe Cases of COVID-19: A Randomized Controlled Trial. *International Immunopharmacology*, 2021. **Dastan F (Corresponding Author)**
35. Yousefian S, Dastan F, Majid Marjani, et al. Determination of Voriconazole Plasma Concentration by HPLC Technique and Evaluating Its Association with Clinical Outcome and Adverse Effects in Patients with Invasive Aspergillosis. *Canadian Journal of Infectious Diseases and Medical Microbiology*, 2021. **Dastan F (Corresponding Author)**
36. Afzal G, Ansari A Z, Beheshti M M, et al. Evaluating the Effect of Acetazolamide on Prevention of Post-operative Acute Kidney Injury after Coronary Artery Bypass Grafting Surgery: A Randomized, Open-Labeled Clinical Trial, *IJPR*, 2021. **Dastan F (Corresponding Author)**
37. Rezaei S, Fatemi B, Karimi Majd Z, et al. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis. *Expert review of clinical immunology*, 2021.
38. Hashemian SM, Shafigh N, Afzal G, et al. Blood Purification Techniques, Inflammatory Mediators and Mortality in COVID-19 Patients. *Tanaffos*, 2020
39. Jamaati H, Hashemian SMR, Dastan F, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial. *European Journal of Pharmacology*, 2021. **Dastan F (Corresponding Author)**
40. Tolouian R, Mulla Z, Dastan F, et al. Effect of Bromhexine in Hospitalized Patients with COVID-19. *Journal of Investigative Medicine*, 2021. **Dastan F (Corresponding Author)**
41. Tabarsi P, Jamaati H, Dastan F, et al. Impact of Clinical Pharmacist-led Antibiotic Stewardship Program on Clinical Outcomes in a Tertiary Referral Hospital. *Journal of Pharmacy Practice and Research*, 2021. **(Corresponding Author)**
42. Jamshidi E, Asgary A, Tavakoli N, et al. Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning. *medRxiv*, 2021.
43. **Dastan F**, Jamshid Salamzadeh, Ali Saffaei, et al. Atorvastatin-Induced Myalgia in Iranian Patients: A Hospital-Based Study to Determine the Prevalence and Associated Risk Factors. *Journal of Pharmaceutical Care*, 2020.
44. Malekzadeh R, Abedini A, Mohsenpour B, et al. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. *International Immunopharmacology*, 2020.
45. Tabarsi P, Barati S, Jamaati H, et al. Evaluating the effects of Intravenous Immunoglobulin (IVIg) on the management of severe COVID-19 cases: A randomized controlled trial *International immunopharmacology*, 2020. **Dastan F (Corresponding Author)**
46. Baghaei P, **Dastan F**, Marjani M, et al. Combination therapy of IFN $\beta$ 1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients. *International Immunopharmacology*, 2020.
47. Yassari A, **Dastan F**, Marashian SM, et al. Can L-Carnitine Supplementation Improve Cardiopulmonary Function? A Randomized Controlled Clinical Trial in Hemodialysis Patients. *Iranian Journal of Kidney Diseases*, 2020.
48. Marjani M, Tabarsi P, Moniri A, et al. NRITLD Protocol for the Management of Patients with COVID-19 Admitted to Hospitals. *Tanaffos*. 2020.
49. Baghaei P, Nadji SA, Marjani M, et al. Clinical Manifestations of Patients with Coronavirus Disease 2019 (COVID-19) in a Referral Center in Iran. *Tanaffos*, 2020.
50. Najafi A, Ghanei M, Janbabaei G, et al. Real Clinical Practice and Therapeutic Management Following COVID-19 Crisis in two Hospitals in Iran: A Statistical and Conceptual View. *Tanaffos*, 2020.

51. Mohammadi Barzelighi H, Daraei B, **F Dastan**. Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review. *Iranian Journal of Pharmaceutical Research*, 2020.
52. Fakharian A, Barati S, Mohamadi M, et al. Successful Management of COVID-19 with Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient. *Journal of Cardiothoracic and Vascular Anesthesia*, 2020. **Dastan F (Corresponding Author)**
53. **Dastan F**, Nadji SA, Saffaei A, et al. Subcutaneous administration of Interferon beta-1a for COVID-19: A non-controlled prospective trial. *International Immunopharmacology*, 2020.
54. **Dastan F**, Nadji SA, Saffaei A, et al. Tocilizumab administration in a refractory case of COVID-19. *International Journal of Antimicrobial Agents*, 2020.
55. **Dastan F**, Saffaei A, Haseli S, Et al. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. *International immunopharmacology*, 2020.
56. Jamaati H, Dastan F, Tabarsi P, et al. A Fourteen-day Experience with Coronavirus Disease 2019 (COVID-19) Induced Acute Respiratory Distress Syndrome (ARDS): An Iranian Treatment Protocol. *IJPR*, 2020. **Dastan F (Corresponding Author)**
57. **Dastan F**, Saffaei A, Mortazavi SM, et al. Continues Renal Replacement Therapy (CRRT) With Disposable Hemoperfusion Cartridge: A Promising Option for Severe COVID-19. *Journal of Global Antimicrobial Resistance*, 2020.
58. Abedini A, Feizabadi F, Kiani A, et al. Potential therapeutic effects of pentoxifylline against COVID-19. *Biomed Biotechnol Res J*, 2020. **Dastan F (Corresponding Author)**
59. Ahmadi ZH, Jahangirifard A, Farzanegan B, et al. Extracorporeal membrane oxygenation and COVID-19: The causes of failure. *Journal of cardiac surgery*, 2020. **Dastan F (Corresponding Author)**
60. Barati S, Jahangirifard A, Ahmadi ZH, et al. The effects of melatonin on the oxidative stress and duration of atrial fibrillation after coronary artery bypass graft surgery: A Randomized Controlled Trial. *Endocrine, Metabolic & Immune Disorders Drug*, 2020. **Dastan F (Corresponding Author) Dastan F**. Evaluating the Potential Effect of L-carnitine on the Prevention of AF Following Coronary Artery Bypass Graft Surgery: A Randomised Clinical Trial. *European Cardiology Review*, 2020.
61. **Dastan F**, Ahmadi ZH, Pourshaban P, et al. Potential effect of coenzyme Q10 (Ubiquinone) on serum NGAL biomarker and kidney function following Coronary Artery Bypass Grafting surgery. *Journal of Cellular & Molecular Anesthesia*, 2020.
62. Jamaati H, **Dastan F**, Esmaili Dolabinjad S, et al. COVID-19 in Iran: A model for Crisis Management and Current Experience. *Iranian Journal of Pharmaceutical Research*, 2020.
63. Jamaati H, Fadaizadeh L, Khoundabi B, et al. COVID-19-Related severe heterogeneous acute respiratory distress syndrome: A therapeutic challenge. *Biomedical and Biotechnology Research Journal*, 2020.
64. **Dastan F**, Ameri A, Dodge S, et al. Efficacy and safety of propolis mouthwash in management of radiotherapy induced oral mucositis: a randomized, double blind clinical trial. *Reports of Practical Oncology & Radiotherapy*, 2020.
65. Yassari F, Eslaminejad A, Marashian M, et al. Can L-Carnitine Supplementation Improve Cardiopulmonary Function? A Randomized Controlled Clinical Trial in Hemodialysis Patients. *Nephrology Dialysis Transplantation*, 2020.
66. **Dastan F**, Abedini A, Shahabi S, et al. Sitagliptin Repositioning in SARS-CoV-2: Effects on ACE-2, CD-26, and Inflammatory Cytokine Storms in the Lung. *Iran J Allergy Asthma Immunol*, 2020.
67. **Dastan F**, Langari ZM, Salamzadeh J, et al. A comparative study of the analgesic effects of intravenous ketorolac, paracetamol, and morphine in patients undergoing video-assisted

- thoracoscopic surgery: A double-blind, active-controlled, randomized clinical trial. *Annals of Cardiac Anaesthesia*, 2020.
68. **Dastan F**, Tabarsi P, Marjani M, et al. Thalidomide against Coronavirus Disease 2019 (COVID-19): A Medicine with a Thousand Faces. *IJPR*, 2020.
  69. Khalili A, Fani K, Naziri M, et al. Effect of L-Carnitine on Troponin, IL6 and HS-CRP levels after Coronary Artery Bypass Graft Surgery. *Journal of Cellular & Molecular Anesthesia*, 2019.
  70. **Dastan F**, Salamzadeh J, Eslamnejad A, et al. Effects of High-Dose Vitamin D Replacement on the Serum Levels of Systemic Inflammatory Biomarkers in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease. *Journal of Chronic Obstructive Pulmonary Disease*, 2019.
  71. Farsad F, **Dastan F**, Salamzadeh J, et al. Assessment of Outpatients' Knowledge and Adherence on Warfarin: The Impact of a Simple Educational Pamphlet. *Iranian Journal of Pharmaceutical Research*, 2019.
  72. **Dastan F**, Salamzadeh J, Alipour-Parsa S, et al. The Potential Effect of Intravenous Calcitriol on the Ischemia-Reperfusion Injury and Inflammatory Biomarkers in Patients following Percutaneous Coronary Intervention (PCI). *IJPR*, 2019.
  73. Bozorg BD, Goodarzi A, Fahimi F, et al. Simultaneous Determination of Isoniazid, Pyrazinamide and Rifampin in Human Plasma by High-performance Liquid Chromatography and UV Detection. *IJPR*, 2019. **Dastan F (Corresponding Author)**
  74. **Dastan F**, Salamzadeh J, Saffaei A, et al. Atorvastatin-Induced Myalgia in Iranian Patients: A Hospital-Based Study to Determine the Prevalence and Associated Risk Factors. *JPC*, 2020.
  75. Pourrashid MH, Dastan F, Salamzadeh J, et al. Role of Vitamin D Replacement on Health Related Quality of Life in Hospitalized Patients with " Acute Exacerbation of Chronic Obstructive Pulmonary Disease". *IJPR*, 2018. **Dastan F (Corresponding Author)**
  76. Jamaati H, Dastan F, Langari ZM, et al. Study Protocol on Antimicrobial Stewardship in a Tertiary Respiratory Referral Hospital. *Tanaffos*, 2018. **Dastan F (Corresponding Author)**
  77. **Dastan F**, Talasaz AH, Mojtahedzadeh M, et al. Randomized trial of carnitine for the prevention of perioperative atrial fibrillation. *Seminars in thoracic and cardiovascular surgery*, 2018.
  78. **Dastan F**, Jamaati H, Emami H, et al. Reducing inappropriate utilization of albumin: the value of pharmacist-led intervention model. *IJPR*, 2018.
  79. **Dastan F**, Talasaz AH, Mojtahedzadeh M, et al. Potential effect of L-carnitine on the prevention of myocardial injury after coronary artery bypass graft surgery. *The Journal of Tehran University Heart Center*, 2015.
  80. **Dastan F**, Bozorg BD, Goodarzi A, et al. Prediction Model of Drug-Induced Liver Injury in Patients with Pulmonary Tuberculosis: Evaluation of the Incidence and Risk Factors. *Journal of Pharmaceutical Care*, 2015.
  81. Talasaz A, Dastan F, Boroumand M, et al. The role of preoperative administration of L-carnitine in the prophylaxis of post CABG atrial fibrillation. *EUROPEAN HEART JOURNAL*, 2014.
  82. Mansouri A, Ahmadvand A, Hadjibabaie M, et al. A review of medication errors in iran: sources, underreporting reasons and preventive measures. *IJPR*, 2014.
  83. Khalili H, Dastan F, Manshadi SAD. A case report of hearing loss post use of hydroxychloroquine in a HIV-infected patient. *DARU Journal of Pharmaceutical Sciences*, 2014.
  84. Fahimi F, Tabarsi P, Kobarfard F, et al. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis. *The International journal of tuberculosis and lung disease*, 2013.



## PhD and PharmD Theses Supervision

1. Determination of Voriconazole concentration by means of HPLC method and evaluating its effects on Clinical outcome in invasive aspergilosis
2. Evaluating prophylactic effects of erythropoietin on blood dyscrasia following heart transplantation
3. Evaluating the efficacy and safety of ATG in the prevention of acute rejection in heart transplantation
4. Evaluating the efficacy and safety of rivaroxaban in comparison with warfarin in patients with chronic thromboembolic pulmonary hypertension undergoing endarterectomy
5. Evaluating the nutritional status of hospitalized patients based on ASPEN guideline and nutritional risk screening
6. Comparing two vitamin D regimen in patients with cystic fibrosis and vitamin D deficiency
7. Evaluating the parents' drug knowledge and its association with quality of life and morbidity markers in pediatrics
8. Evaluation of propolis solution on the prevention of oral mucositis in patients undergone head and neck radiotherapy
9. Comparison of analgesic effects of Morphine with Ketorolac and Paracetamol in patients undergone videothoracoscopic surgery
10. Q10 effects on the prevention of acute kidney injury following CABG surgery
11. Evaluating statin-induced myopathy and related risk factors in hospitalized patients
12. Evaluating clinical pharmacist role on therapeutic and clinical outcomes in patients with heart transplantation
13. Evaluation of medication errors in intravenous antimicrobial administration in NICU wards
14. Evaluating the effects of IV Colistin in combination with inhaled Colistin in MDR VAP
15. Evaluation of the effects of economic factors on the rate of respiratory patients drug adherence
16. Assessment of the reasons for delay in thromboprophylaxis initiation in hospitalized patients
17. Evaluation of cost related drug non-adherence in adult asmathic patients and the related risk factors
18. Comparison of two methods of data gathering (paper based vs electronical) on antibiotic stewardship program
19. Evaluation of cost related drug non-adherence in patients following angioplasty
20. Evaluating the medication beliefs in patients with asthma and the related factors
21. Assessment of drug utilization assessment in patients with thromboemboli in orthopedic ward
22. Evaluating the role of pharmacist on education of patients with vaginal discharge: a CAP study
23. Evaluating the anti-cancerous effects of nano-bound paclitaxel loaded on amniotic epithelial cells
24. Evaluating the effects of medication card on medication errors in IV drug administration
25. Assessment of drug adherence in patients with lung fibrosis
26. Assessment of drug adherence in patients undergone heart or lung transplantation
27. Evaluating IV calcitriol effects on ischemia-reperfusion injury and inflammatory cytokines in PCI, **As supervisor of Ph.D. level thesis**
28. Assessment of Melatonin effects on AF and AKI incidence in CABG patients, **As supervisor of Ph.D. level thesis**

29. Vit D effects on prognostic factors in patients with AECOPD, **As supervisor of Ph.D. level thesis**
30. Evaluation the the efficacy and safety of Umifenovir (Arbidol) Administration in comparison with Lopinavir-ritonavir (Kaletra) in COVID-19 patient
31. Evaluating the therapeutic and adverse effects of Interferon beta 1-a subcutaneous administration in patients with new Coronavirus (COVID-19)
32. Evaluation the efficacy and safety of intravenous immunoglobulin (IVIG) in COVID-19 patients
33. Evaluation the efficacy and safety of Favipiravir Administration in comparison with Lopinavir-ritonavir in COVID-19
34. Evaluating the effect of agomelatine on CPAP adherence in patients with obstructive sleep apnea
35. The investigation of Sitagliptin on control and improvement of patients with COVID-19
36. The therapeutic effects of Pirfenidone in patients with pulmonary fibrosis after COVID-19 pneumonia
37. A Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Bromhexine, A Serine protease [TMPRSS2] blocker and mucolytic, in Hospitalized Adult Patients with 2019-nCoVRespiratory Disease
38. Investigating the effect of almond sweet, Oral product, as a supplement in patients with COVID 19
39. Evaluation of the effect of Bromhexine prophylaxis on the onset of symptoms and reduction of clinical complications in the family of patients with covid 19
40. COVID-19 in IRAN: Current Experience in Masih Daneshvari Hospiatal
41. Effects of Favipiravir on Clinical Situation, Laboratory and Imaging Findings and Outcome of COVID-19 among Referrals to a University Hospital in Tehran
42. Investigation of Demographic and Laboratory Characteristics and Therapeutic Interventions in patients who died of coronavirus
43. Evaluation the efficacy and safety of Favipiravir in comparison with Lopinavir-ritonavir resistance cases in COVID-19 patients
44. Developing a model to determine the association between clinical and laboratory futures of COVID-19 cases and clinical outcomes
45. Evolution of the efficacy and safety of Dexamethasone administration in patients with mild to moderate COVID-19 acute respiratory disease syndrome
46. Evaluation the Efficacy and Safety of Tocilizumab in Patients with Novel Coronavirus (COVID-19)
47. Evaluating the Effect of Acetazolamide on Prevention of Post-operative Acute Kidney Injury after Coronary Artery Bypass Grafting Surgery: A Randomized, Open-Labeled Clinical Trial, **As supervisor of Ph.D. level thesis**
48. Study of the effects of Melatonin on sleep disorders in pulmonary sarcoidosis patients, **As supervisor of Ph.D. level thesis**
49. Evaluation of Adalimumab Effects in Managing Severe Cases of COVID-19: A Randomized Controlled Trial

## Poster and Oral Presentations

No	Issue	Poster/Oral	Country	Title	Date	Name of Congree
1	Drug adherence	Poster	Japan	Adherence to respiratory medication therapy among Iranian patients	2018 Sep	ISPOR Asia Pacific

2	Antimicrobial treatment	Oral	Netherlands	Comparison of aerosolized colistin as adjunctive treatment versus IV Colistin alone in treatment of VAP caused by MDR pathogens	2018	ISCOMS
3	Cardiovascular disease	Oral	Iran	DVT: case-based approach	2019	Updates in CVD Congress
4	Pharmaceutical care	Oral	Iran	Drugs in ICU	2019	Critical Care Congress
5	Antimicrobial approach	Oral	Iran	AS colistin as adjunctive treatment versus IV colistin in treatment of VAP caused by MDR	2018	Asian clinical pharmacy congress
6	ADR	Oral	Iran	Pharmacovigilance	2018	Monthly Nursing symposium
7	Pharmacovigilance	Oral	Iran	Cardiovascular Adverse Drug Reaction of medications	2018 May	Monthly Nursing symposium
8	Medication Errors	Oral	Iran	Medication Errors	2018	Monthly Nursing symposium
9	Cardiovascular surgery complications	Poster	Germany	L-carnitine in CABG	2017 Sep	ESC Congress
10	Pharmacokinetics	Oral	Iran	Pharmacokinetic in ICU	2018 Jun	Asian ACCP
11	ADR	Poster	Iran	Statin-induced myopathy	2018 Jun	Asian ACCP
12	VTE prophylaxis	Poster	Iran	Delay in VTE prophylaxis	2018 Jun	Asian ACCP
13	Cardiovascular surgery complications	Poster	Iran	Q10 in CABG	2018 Jun	Asian ACCP
14	Pharmacotherapy	Oral	Iran	Transplantation pharmacotherapy and immunosuppressive therapy	2017	Heart Transplantation Symposium
15	DUE	Poster	Iran	Reducing inappropriate utilization of albumin: the value of pharmacist-led intervention model	2017	First Euro-Asian Congress of Pharmacoepidemiology
16	Mucositis	Poster	Iran	Propolis in oral mucositis in head and neck radiotherapy	2016	28th Cancer Institute Yearly Congress
17	Patient safety	Oral	Iran	Medication Reconciliation Implementation	2016	Medication Reconciliation Workshop
18	Cardiovascular Disease	E-	San Francisco	Possible effect of L-carnitine on the prevention of AF in CABG patients	2014	2nd Clinical Pharmacy Conference
19	Pharmacology	Presentation	Netherlands	Tamoxifen alters hormonal levels in adult rats and folliculogenesis in fetus	2014	ISCOMS
20	Pharmacotherapy	Oral	Iran	Principles of personalized drug therapy	2019 Mar	10th Iranian Clinical Pharmacy Congress
21	Pharmacotherapy	Oral	Iran	Approach to common medication cases in CVD	2019 Mar	10th Iranian Clinical Pharmacy Congress
22	Pharmacovigilance	Oral	Iran	DOACs in pharmacy	2019 Mar	10th Iranian Clinical Pharmacy Congress
23	Pharmacotherapy	Oral	Iran	Assessment of awareness and attitude of senior pharmacy students towards pharmacovigilance in Tehran, Iran	2019 Mar	10th Iranian Clinical Pharmacy Congress

24	Heart transplantation	Poster	Iran	Cardioplegic solutions in coronary artery bypass grafting	2019 Mar	10th Iranian Clinical Pharmacy Congress
25	Pharmacokinetics	Poster	Iran	The prophylactic effect of EPO alfa on drug-induced blood dyscrasia...	2019 Mar	10th Iranian Clinical Pharmacy Congress
26	Pharmacotherapy	Poster	Iran	Evaluating the association between the dose and the concentration of voriconazole	2019	10th Iranian Clinical Pharmacy Congress
27	Pharmacotherapy	Oral	Iran	Effect of IV calcitriol on ischemia reperfusion	2019	10th Iranian Clinical Pharmacy Congress
28	Pharmacotherapy	Oral	Iran	Evaluating the effect of sublingual melatonin on the prevention of AF	2019	10th Iranian Clinical Pharmacy Congress
29	Cardiovascular disease	Oral	Iran	DOACs in DVT	2019 Aug	21st International Congress on CV updates
30	Cardiovascular disease pharmacotherapy	Oral	Iran	PCSK9 inhibitors	2019 Aug	21st International Congress on CV updates
31	Cardiovascular disease pharmacotherapy	Oral	Iran	Anticoagulants updates	2019	18th congress of Iranian Association of Pharmacists
32	ADR	Oral	France	Evaluating the effect of melatonin on AF	2019 Sep	ESC Congress
33	Pharmacotherapy	Poster	Iran	Heparin-induced Thrombocytopenia	2016 Aug	Thrombosis Symposium
34	Pharmacotherapy	Oral	Iran	Tuberculosis- HIV/AIDS pharmacotherapy	2016 Sep	JICA
35	CABG, AF	Oral	Iran	CVD pharmacotherapy updates	2016 Jun	Iranian Clinical Pharmacy Congress
36	CVD	Oral	Netherlands	Ptential effects of L-carnitin on prophylaxis	2016 Jun	ISCOMS
37	Drug safety	Oral	Iran	Hyperlipidemia and Obesity Pharmacotherapy	2018	Seminar on the risk factors for cardiovascular disease
38	Drug safety	Oral	Iran	Safety Issues in Drug Management	2017	Shahid Beheshti University Vice Chancellor for Treatment
39	Drug safety	Oral	Iran	Drug Dosing and Calculations	2017	General course with care level 2 special sections
40	Pharmacotherapy	Oral	Iran	Drug management in ICU	2018	General course with care level 2 special sections
41	Pharmacotherapy	Oral	Iran	Anticoagulants in Surgeries	2019	Congress of Blood Transfusion Organization

## Invited Speaker at International Conferences

- Joint 7<sup>th</sup> International Iranian Heart Failure Summit; 2023 (Speaker and Moderator of Panel)
- 8<sup>th</sup> International of Congress on Critical Care, Tehran, Iran; 2023 (Keynote Speaker)
- 27<sup>th</sup> Annual Scientific Meeting of International Society of Cardiovascular Pharmacotherapy, Bucharest, Romania; 2022 (Poster Presentation)

- Clinical Pharmacy and Research Webinar, Young Researchers Session, London, UK; 2021
- International Congress of Cardiac Anesthesiology & ECMO; 2021 (Speaker & Moderator)
- 5th International USERN Congress and Prize Awarding Festival; 2020 (Universal Scientific Education and Research Network) (keynote Speaker & Panelist)
- 10th Iranian Clinical Pharmacy Congress; 2019 (scientific secretary)
- Asian-European Pharmacoepidemiology; 2019
- European Society of Cardiology Congress, Germany; 2018
- ISPOR Asia Pacific, Japan; 2018
- ACCP (Asian Conference on Clinical Pharmacy); 2018
- International Congress of Pharmacy Updates; 2018 (scientific committee)
- European Society of Cardiology Congress; 2018
- Asian-European Pharmacoepidemiology; 2018
- 28th Annual Congress of Cancer Institute; 2017
- Asian Clinical Pharmacy Congress; 2017
- JICA (Japan International Cooperation Agency); 2016
- 21st International Student Congress of Medical Sciences (ISCOMS); 2014, Netherlands
- 21st International Medical Sciences Congress, Turkey; 2008
- 10th Iranian Pharmaceutical Sciences Conference; 2006
- All Annually Iranian Clinical Pharmacy Congresses; 2011-2020
- 5th International Congress of Oral and Maxillofacial Surgeons

## Books

1. Collection of Separation Questions for the 28th Comprehensive Pharmaceutical Science Basic Exam, Teymourzadeh Publications
2. Symptom Prediction and Mortality Risk Calculation for COVID-19 Using Machine Learning, in *AI-enabled Data Science for COVID-19*, Frontiers in Artificial Intelligence and Frontiers in Big Data, 2022
3. Clinical Pharmacotherapy Protocols, Arjmand Publications
4. Comprehensive textbook of drug therapy, Iranian Association of Clinical Pharmacists
5. Golden Points in Pharmacotherapy (Etminan Publications)
6. National Guideline of COVID-19, Vice- Chancellor's Office in Treatment Affairs, Ministry of Health and Medical Education
7. National Guideline of ECMO in patients with heart failure and COVID-19, Vice- Chancellor's Office in Treatment Affairs, Ministry of Health and Medical Education
8. Patients Guidance Following Discharge in COVID-19

## Workshops

1. RCT-GCP certification from Iranian Registry of Clinical Trials
2. ECMEC Certification from European Society of Cardiology
3. Certificate of basic and advanced vital measures (BLS / ACLS) in the 5th International Congress of the Iranian Society of Oral and Maxillofacial Surgeons
4. Teaching in the retraining of the Iranian Association of Clinical Pharmacologists
5. Device analysis and skills in working with HPLC
6. SPSS software
7. Teaching methods and art of expression

Last update: Oct 2023